Showing 8701-8710 of 9746 results for "".
- Ouchless Needle Announces First Exclusive International Distribution Agreement with Device Technologieshttps://practicaldermatology.com/news/20120501-ouchless_needle_announces_first_exclusive_international_distribution_agreement_with_device_technologies/2459811/Ouchless Needle by the BellaNovus Development Company announced their first international exclusive distribution agreement with Device Technologies for Australia and New Zealand. Developed by aesthetic plastic surgery innovator Marc J. Sa
- PreCision Dermatology Acquires Assets of Triax Pharmaceuticalshttps://practicaldermatology.com/news/20120430-precision_dermatology_acquires_assets_of_triax_pharmaceuticals/2459813/PreCision Dermatology has acquired the assets of Triax Pharmaceuticals LLC, a specialty pharmaceutical company with products including the mid-potency topical steroid Locoid, as well as Minocin and Tretin-X. Onset Dermatologics, the prescrip
- Enrollments Complete for Two Phase 2 ALA-PDT AK Trialshttps://practicaldermatology.com/news/20120424-enrollments_complete_for_two_phase_2_ala-pdt_ak_trials/2459815/DUSA Pharmaceuticals (NASDAQ GM: DUSA) completed patient enrollment in its Phase 2 clinical trial studying the broad area application with 1-, 2-, and 3-hour drug incubation for the treatment of actinic keratoses (AKs) of the face or scalp
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.
- Efficacy Data for LaViv Now Publishedhttps://practicaldermatology.com/news/20120418-efficacy_data_for_laviv_now_published/2459822/Data demonstrating that LaViv (azficel-T, Fibrocell Science, Inc.) is effective for the aesthetic improvement of moderate to severe smile lines are now published online in Dermatologic Surgery. The combined results of two identically-designed, Phase III, multi-
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos
- Lumenis Unveiling New Laser Capability at ASLMShttps://practicaldermatology.com/news/20120413-lumenis_unveiling_new_laser_capability_at_aslms/2459826/Lumenis will unveil UltraPulse's new SCAAR FX CO2 laser treatment capability at the American Society for Laser Medicine and Surgery (ASLMS) annual meeting in Kissimmee, FL. Using up to 150mJoules per pulse, the high energy impact and precision o
- Warning for Blood Clot Risk Added to Drospirenone OCPshttps://practicaldermatology.com/news/20120411-warning_for_blood_clot_risk_added_to_drospirenone_ocps/2459827/The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred t
- Vichy Partners With timeRAZOR for Free iPhone, Android Apphttps://practicaldermatology.com/news/20120404-vichy_partners_with_timerazor_for_free_iphone_android_app/2459828/With the new timeRAZOR app, Vichy and timeRAZOR help keep users in the know on events occurring close to where they work, live, or plan to be. timeRAZOR pairs technologic components like geolocation with its own Massive Event Selection Engine, i
- Prostaglandin D2 A Potential New Target for Alopecia Therapyhttps://practicaldermatology.com/news/20120326-prostaglandin_d2_a_potential_new_target_for_alopecia_therapy/2459832/Prostaglandin D2 (PGD2) appears to inhibit hair growth in androgenetic alopecia (AGA) and may be potential target for its treatment, new research suggests (Sci Transl Med. 4(126):126ra34). Researchers show that PG